
|Articles|July 1, 2003
Novel Nanoparticle Formulation Fights SCC
Chicago - A novel nanoparticle formulation of paclitaxel (ABI-007) administered intra-arterially has been shown to be well tolerated and very active against squamous carcinomas of the head and neck, uterus, and anal canal, Bruno Damascelli, M.D., said at the 39th annual meeting of the American Society of Clinical Oncology.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
2
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
3
Oral STAT6 Degrader KT-621 Shows Biologic-Comparable Activity in Atopic Dermatitis
4
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
5














